Sunitinib in the therapy of malignant paragangliomas: report on the efficacy in a SDHB mutation carrier and review of the literature-Reference-Cited by-同舟云学术

Sunitinib in the therapy of malignant paragangliomas: report on the efficacy in a SDHB mutation carrier and review of the literature

Published:2017-02 Issue:1 Volume:61 Page:90-97
ISSN:2359-3997
Container-title:Archives of Endocrinology and Metabolism
language:
Short-container-title:Arch. Endocrinol. Metab.

Author:

Canu Letizia¹,Pradella Silvia²,Rapizzi Elena¹,Fucci Rossella¹,Valeri Andrea²,Briganti Vittorio²,Giachè Valentino¹,Parenti Gabriele²,Ercolino Tonino¹,Mannelli Massimo¹

Affiliation:

1. University of Florence, Italy

2. Azienda Ospedaliera-Universitaria Careggi, Italy

Publisher

Archives of Endocrinology and Metabolism

Subject

Endocrinology, Diabetes and Metabolism

Link

http://www.scielo.br/pdf/aem/v61n1/2359-3997-aem-2359-3997000000217.pdf

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial;European Journal of Cancer;2024-09

2. Metastatic paraganglioma presenting with spinal cord compression requiring urgent surgery;BMJ Case Reports;2023-09

3. Succinate as an Oncometabolite in Endocrine, Mesenchymal, and Epithelial Tumors;Iranian Red Crescent Medical Journal;2022-11-19

4. Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients with Metastatic Pheochromocytomas/Paragangliomas;The Journal of Clinical Endocrinology & Metabolism;2022-11-16

5. Sunitinib Treatment for Advanced Paraganglioma: Case Report of a Novel SDHD Gene Mutation Variant and Systematic Review of the Literature;Frontiers in Oncology;2021-06-17